Boehringer Ingelheim Expands GeneGo Licenses to Global Agreement
News Apr 10, 2007
The agreement covers a suite of software tools and databases for functional data analysis MetaCore, which is used for biomarker discovery, target identification and validation.
MetaCore features a set of tools for parsing, visualization and analysis of metabolic data and generation of merged metabolic/signaling networks starting from compounds structures. Such capability is key for toxicity studies and medicinal chemistry.
"We have been working for Boehringer Ingelheim more than a year and we are very pleased with their decision to expand their licenses. This year, we have already seen a substantial increase in the number of MetaCore seats within Pharmaceutical accounts, which is partly due to maturing of functional analysis technology," said Julie Bryant, GeneGo's VP of Business Development.
"We also think that the end users, wet lab scientists, see biologically relevant results using MetaCore that they are not getting from other tools," Bryant added.
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE